Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

569229-U

Supelco

Discovery® C18 (5 µm) HPLC Columns

L × I.D. 12.5 cm × 2.1 mm, HPLC Column

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® C18 HPLC Column, 5 μm particle size, L × I.D. 12.5 cm × 2.1 mm

material

stainless steel column

Agency

suitable for USP L1

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

12% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

12.5 cm × 2.1 mm

surface area

300 m2/g

surface coverage

3 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical particle platform
fully porous particle

matrix active group

C18 (octadecyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Use Discovery® C18 for any method that specifies a C18. The exceptional peak shape, reproducibility, and stability make it the column of choice for all C18 methods from demanding to routine.

Features and Benefits

  • Excellent reproducibility
  • Exceptional peak shape for basic and acidic analytes
  • Stable, low-bleed LC-MS separations
  • Separation of peptides and small proteins
  • Lower hydrophobicity than many comparable C18 columns, providing faster analysis

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
280052-01
280051-01
279629-01
279617-01
279079-01

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T R Shantha Kumar et al.
Journal of pharmaceutical and biomedical analysis, 38(1), 173-179 (2005-05-24)
A simple, precise and accurate isocratic reverse-phase liquid chromatography method with programmed wavelength detection has been validated to quantify DRF-4367 and Phenol red, simultaneously for application in rat in situ single pass intestinal perfusion study to assess intestinal permeability of
Abbas Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(24), 2423-2429 (2011-07-26)
A novel isocratic reversed-phase high performance liquid-chromatography/ultraviolet detection method for simultaneous determination of cefdinir and cefixime in human plasma was developed and validated after optimization of various chromatographic conditions and other experimental parameters. Sample preparation based on a simple extraction
Ramisetti Nageswara Rao et al.
Journal of separation science, 32(9), 1312-1322 (2009-04-29)
Modafinil, adrafinil and their related substances were synthesized and analyzed by RP-LC with ESI-MS/MS. The ionization mode, polarity, cone voltage, and chromatographic conditions were evaluated. The optimum LC-MS conditions to obtain fragment ions indispensable for identification of the structures were
Himal Paudel Chhetri et al.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 22(5), 483-487 (2014-12-05)
This study presents the optimization of a simple HPLC-UV method for the determination of metformin in human plasma. Ion pair separation followed by UV detection was performed on deproteinized human plasma samples. The separation was carried out on a Discovery
Sheelendra Pratap Singh et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(27), 2845-2851 (2011-09-06)
Tamoxifen is the agent of choice for the treatment of estrogen receptor-positive breast cancer. Tamoxifen is a substrate of P-glycoprotein (P-gp) and microsomal cytochrome P450 (CYP) 3A, and biochanin A (BCA) is an inhibitor of P-gp and CYP3A. Hence, it
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service